Oct 17, 2025 (PRISM News via COMTEX) --
Boston Scientific Corporation (NYSE: BSX) has announced a definitive agreement to acquire Nalu Medical, a private medical technology company known for its innovative, minimally invasive solutions for chronic pain. The move is set to broaden Boston Scientific’s neuromodulation offerings for patients suffering from persistent pain conditions.
The transaction involves an upfront cash payment of approximately $533 million for the remaining equity in Nalu Medical that Boston Scientific does not already own. Having been a strategic investor in Nalu Medical since 2017, Boston Scientific is now moving to fully integrate the company’s technology into its portfolio. The total transaction price is valued at $600 million on a 100% basis.
At the heart of the acquisition is the Nalu Neurostimulation System, a device designed to provide targeted relief for adults with severe, intractable chronic pain originating from peripheral nerves. This therapy, known as peripheral nerve stimulation (PNS), uses mild electrical impulses to interrupt pain signals before they reach the brain. It is used to treat pain in areas like the shoulder, lower back, and knee.
The Nalu system features a miniaturized, battery-free implantable pulse generator. This implant is powered wirelessly by a small, externally worn therapy disc and can be controlled through a smartphone application, offering a modern and convenient approach for patients.
Since receiving FDA 510(k) clearance in 2019, the Nalu system has demonstrated significant and sustained pain relief in clinical trials. The COMFORT trial showed that 87% of participants experienced more than a 50% reduction in pain at 12 months. Similarly, the COMFORT 2 trial found that 79% of patients achieved an average pain relief of 64% at the six-month mark. These results have been further supported by real-world data from over 2,000 individuals, where 94% of patients reported clinically meaningful improvement across a range of chronic peripheral nerve pain conditions.
“Peripheral nerve stimulation is an exciting field with a significant unmet patient need,” said Jim Cassidy, president of Neuromodulation at Boston Scientific. “Adding the highly differentiated Nalu Medical technology complements our existing therapies--including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation--enabling us to deliver advanced pain relief options to a wider variety of patient populations.”
Boston Scientific anticipates the transaction will close in the first half of 2026, pending customary closing conditions. Financially, Nalu Medical is projected to generate over $60 million in sales in 2025 and is expected to see year-over-year growth exceeding 25% in 2026. While the acquisition is expected to be immaterial to adjusted earnings per share (EPS) in 2026, it is projected to become slightly accretive in 2027 and increasingly so in the following years. On a GAAP basis, the transaction is expected to be more dilutive due to amortization expenses and other acquisition-related charges.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
The post Boston Scientific to Acquire Nalu Medical, Expanding its Chronic Pain Treatment Portfolio appeared first on PRISM MarketView.
COMTEX_469585452/2927/2025-10-17T08:30:22
